Acute B-cell Lymphoblastic Leukemia
Conditions
Keywords
Acute B-cell lymphoblastic leukemia, Relapse, allogeneic hematopoietic stem cell transplantation, Blinatumomab
Brief summary
B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab. Anti-treatment was followed by DLI, and the second course was performed 1-2 months after DLI. Patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment. (MNC infusion is about 5×10\^7/kg\ 1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\ 1×10\^8/kg). Objective To observe and analyze the efficacy and side effects of Blinatumomab followed by donor lymphocyte infusion in patients with relapsed acute B lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation in our hospital.
Detailed description
Patients with acute B-cell lymphoblastic leukemia who relapsed after receiving allogeneic hematopoietic stem cell transplantation in our hospital and received sequential donor lymphocyte infusion （DLI） treatment after relapse. The patients with acute B-cell lymphoblastic leukemia who relapsed after receiving allogeneic hematopoietic stem cell transplantation in our hospital from September 2023 to December 2026 and received sequential donor lymphocyte infusion （DLI） treatment after relapse were enrolled. 1. Age ≤65 years old 2. Stable vital signs 3. No severe infection 4. No grade II-IV graft-versus-host disease 5. No organ failure Exclusion criteria 1. Age \>65 years old 2. Unstable vital signs 3. Complicated with severe infection 4. Complicated with grade II-IV graft-versus-host disease 5. Organ failure such as heart, liver, kidney, etc. 6. Complicated with central nervous system leukemia 7. Drug allergy to the treatment regimen Treatment regimen B-ALL patients were regularly followed up after allogeneic hematopoietic stem cell transplantation. When relapse occurred, Blinatumomab was given sequentially after DLI, and the second course of treatment was conducted 1-2 months after DLI. MRD-positive patients were given Blinatumomab 28μg×5-15 days, followed by DLI treatment （infusion of MNC is about 5×10\^7/kg\ 1×10\^8/kg）. Hematologic relapse patients were given Blinatumomab 9μg d1-4,11.66μg d5-7,28μg d8 （a total of 8 to 21 days）, followed by DLI treatment （infusion of MNC is about 5×10\^7/kg\ 1×10\^8/kg）. The duration of using Blinatumomab was determined according to the patient's tolerance, economic situation and other comprehensive factors. Main observation and statistical indicators Overall survival after relapse, disease-free survival, incidence of cytokine release syndrome （CRS）, incidence of acute/chronic graft-versus-host disease （GVHD） after treatment, incidence of infection, incidence of hematological adverse reactions, etc.Compared with patients receiving usual care.
Interventions
DRUGBlinatumomab
patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment. (MNC infusion is about 5×10\^7/kg\ 1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\ 1×10\^8/kg).
Sponsors
Suping ZHANG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≤65 years old 2. Stable vital signs 3. No severe infection 4. There was no grade II-IV graft-versus-host disease 5. No organ failure
Exclusion criteria
1. Age \> 65 years old 2. Unstable vital signs 3. Complicated with severe infection 4. Combined with grade Ⅱ-Ⅳ graft-versus-host disease 5. Heart, liver, kidney and other organ failure 6. Complicated with central nervous system leukemia 7. Allergies to medications in the treatment regimen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | three years | Survival time of patients with recurrence after treatment |
| Disease-free survival | three years | Disease-free survival time after treatment for relapsed patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence of cytokine release syndrome （CRS） | 2 weeks later | Recurrent patients received treatment 2 weeks later |
| Incidence of acute/chronic graft-versus-host disease （GVHD） | 2 weeks later | Recurrent patients received treatment 100 days later. |
| hematological adverse reactions Incidence rate | 2 weeks later | Recurrent patients received treatment 2 weeks later. |
Countries
China
Contacts
Primary ContactSuping ZHANG
Backup ContactZhilei BIAN
Outcome results
None listed